News
President Donald Trump is continuing to promote the unsupported “lab leak” COVID-19 theory, using it now to rationalize a ...
Mersana Therapeutics only has eyes for Emi-Le. Seeking to extend its cash runway into mid-2026, the biotech is laying off 55% ...
The National Institutes of Health (NIH) has laid off 250 more employees, with this round of cuts hitting 50 workers at the ...
Anti-aging biotech NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a ...
Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue, while reporting ...
Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...
Abbott’s rapid, blood-based test for concussions is making its sporting debut through the motorcycle racing series ...
The FDA elevated a recall of intraocular lenses currently being wrapped up by Bausch + Lomb, following increased reports of ...
A phase 3 trial of Aldeyra Therapeutics’ dry eye disease prospect has hit its primary endpoint, teeing the biotech to seek ...
Capricor Therapeutics saw its shares fall 13% by the end of trading Monday as its investigational cell therapy deramiocel for ...
PTC Therapeutics reported a phase 2 win for its Novartis-partne | PTC Therapeutics reported a phase 2 win for its ...
Masimo disclosed that a cyber attack on its systems has hit its manufacturing facilities, slowing production at the remote patient monitoring company. | Masimo has disclosed that a cyber attack on its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results